002020 京新药业
已收盘 07-24 15:00:00
资讯
新帖
简况
京新药业:京诺宁的推广工作正在有序进行,进展顺利。具体数据烦请关注公司定期报告或相关公告
证券之星 · 07-17
京新药业:京诺宁的推广工作正在有序进行,进展顺利。具体数据烦请关注公司定期报告或相关公告
京新药业:公司正在为京诺宁即将到来的医保谈判做材料准备
证券之星 · 07-03
京新药业:公司正在为京诺宁即将到来的医保谈判做材料准备
京新药业(002020.SZ):恩诺沙星原料药获得欧洲药品质量管理局CEP证书
智通财经 · 06-23
京新药业(002020.SZ):恩诺沙星原料药获得欧洲药品质量管理局CEP证书
京新药业最新公告:子公司恩诺沙星原料药获得欧洲CEP证书
证券之星 · 06-23
京新药业最新公告:子公司恩诺沙星原料药获得欧洲CEP证书
京新药业:公司与万邦医药没有关系
证券之星 · 06-20
京新药业:公司与万邦医药没有关系
京新药业(002020)6月19日主力资金净卖出2194.77万元
证券之星 · 06-20
京新药业(002020)6月19日主力资金净卖出2194.77万元
京新药业:该项目的国外合作方还在申报FDA阶段,目前正在跟进进展
证券之星 · 06-07
京新药业:该项目的国外合作方还在申报FDA阶段,目前正在跟进进展
京新药业:公司经营一切正常,不存在ST风险
证券之星 · 06-03
京新药业:公司经营一切正常,不存在ST风险
京新药业:公司人工大血管项目目前已经进入到小规模人体试验阶段
证券之星 · 05-30
京新药业:公司人工大血管项目目前已经进入到小规模人体试验阶段
京新药业:由于京诺宁是精二类管制品种,只能在院内处方和配药,因此入院工作在前期至关重要
证券之星 · 05-24
京新药业:由于京诺宁是精二类管制品种,只能在院内处方和配药,因此入院工作在前期至关重要
京新药业:主要是费用的年度预提
证券之星 · 05-21
京新药业:主要是费用的年度预提
京新药业(002020.SZ)2023年度权益分派:每10股派3元 股权登记日5月23日
智通财经 · 05-16
京新药业(002020.SZ)2023年度权益分派:每10股派3元 股权登记日5月23日
京新药业:年度股东大会已经通过年度分红议案,公司将在规定时间内完成
证券之星 · 05-09
京新药业:年度股东大会已经通过年度分红议案,公司将在规定时间内完成
京新药业:公司暂无扩大睿泰投资的计划
证券之星 · 05-08
京新药业:公司暂无扩大睿泰投资的计划
京新药业公布国际专利申请:“配体-寡核苷酸共轭物及用于该共轭物的接头”
证券之星 · 05-04
京新药业公布国际专利申请:“配体-寡核苷酸共轭物及用于该共轭物的接头”
京新药业:针对京诺宁,公司目前仍然以国内市场为重点,时机合适也将推动海外市场拓展
证券之星 · 04-29
京新药业:针对京诺宁,公司目前仍然以国内市场为重点,时机合适也将推动海外市场拓展
京新药业获得发明专利授权:“一种左乙拉西坦的制备方法”
证券之星 · 04-27
京新药业获得发明专利授权:“一种左乙拉西坦的制备方法”
太平洋:给予京新药业买入评级,目标价位18.42元
证券之星 · 04-25
太平洋:给予京新药业买入评级,目标价位18.42元
京新药业(002020)2024年一季报简析:营收净利润同比双双增长,盈利能力上升
证券之星 · 04-25
京新药业(002020)2024年一季报简析:营收净利润同比双双增长,盈利能力上升
平安证券:给予京新药业增持评级
证券之星 · 04-24
平安证券:给予京新药业增持评级
加载更多
公司概况
公司名称:
浙江京新药业股份有限公司
所属行业:
医药制造业
上市日期:
2004-07-15
主营业务:
浙江京新药业股份有限公司主要从事化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品为心脑血管药物、神经系统药物、消化系统药物、呼吸系统药物、泌尿生殖系统药物、喹诺酮类抗感染原料药、他汀类原料药、精神类原料药、定制化医用显示器和HMI、标准化医用显示器及医疗影像解决方案。公司是第一批“中国医药企业制剂国际化先导企业”,连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。
发行价格:
10.05
{"stockData":{"symbol":"002020","market":"SZ","secType":"STK","nameCN":"京新药业","latestPrice":10.26,"timestamp":1721804583000,"preClose":10.53,"halted":0,"volume":10987200,"delay":0,"floatShares":656000000,"shares":861000000,"eps":0.7421,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.27,"latestTime":"07-24 15:00:00","open":10.5,"high":10.56,"low":10.22,"amount":114000000,"amplitude":0.0323,"askPrice":10.27,"askSize":182,"bidPrice":10.26,"bidSize":28,"shortable":0,"etf":0,"ttmEps":0.7421,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721871000000},"adr":0,"adjPreClose":10.53,"symbolType":"stock","openAndCloseTimeList":[[1721784600000,1721791800000],[1721797200000,1721804400000]],"highLimit":11.58,"lowLimit":9.48,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":861029140,"pbRate":1.6,"roa":"--","roe":"3.06%","epsLYR":0.72,"committee":-0.246428,"marketValue":8834000000,"floatMarketCap":6735000000,"peRate":13.82563,"changeRate":-0.0256,"turnoverRate":0.0167,"status":1},"requestUrl":"/m/hq/s/002020","defaultTab":"news","newsList":[{"id":"2452663561","title":"京新药业:京诺宁的推广工作正在有序进行,进展顺利。具体数据烦请关注公司定期报告或相关公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2452663561","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452663561?lang=zh_cn&edition=full","pubTime":"2024-07-17 23:00","pubTimestamp":1721228439,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)07月17日在投资者关系平台上答复投资者关心的问题。投资者:请问公司新药入院多少家?销量如何?京新药业董秘:您好!京诺宁的推广工作正在有序进行,进展顺利。具体数据烦请关注公司定期报告或相关公告。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700045092.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2448779261","title":"京新药业:公司正在为京诺宁即将到来的医保谈判做材料准备","url":"https://stock-news.laohu8.com/highlight/detail?id=2448779261","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448779261?lang=zh_cn&edition=full","pubTime":"2024-07-03 18:04","pubTimestamp":1720001064,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业07月03日在投资者关系平台上答复投资者关心的问题。公司正在为京诺宁即将到来的医保谈判做材料准备。目前公司暂无其他产品涉及进入医保。公司上半年营收如何?京诺宁的入院以及销售工作正在有序进行。公司目前经营状况正常,具体经营数据请关注后续披露的定期报告。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070300037636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2445203189","title":"京新药业(002020.SZ):恩诺沙星原料药获得欧洲药品质量管理局CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2445203189","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445203189?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:48","pubTimestamp":1719132486,"startTime":"0","endTime":"0","summary":"智通财经APP讯,京新药业(002020.SZ)发布公告,公司全资子公司绍兴京新药业有限公司(简称“绍兴京新”)收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书(简称“CEP证书”)。原料药名称为ENROFLOXACIN/恩诺沙星,恩诺沙星属于喹诺酮类化学合成抑菌剂,主要用于治疗动物的感染性疾病。对支原体、大肠杆菌、克雷白杆菌、沙门氏菌、变形杆菌、绿脓杆菌等都有杀灭效用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2445039952","title":"京新药业最新公告:子公司恩诺沙星原料药获得欧洲CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2445039952","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445039952?lang=zh_cn&edition=full","pubTime":"2024-06-23 16:30","pubTimestamp":1719131430,"startTime":"0","endTime":"0","summary":"京新药业公告,子公司绍兴京新药业有限公司收到欧洲药品质量管理局签发的原料药欧洲药典适用性证书(CEP证书)。原料药名称:ENROFLOXACIN/恩诺沙星。恩诺沙星属于喹诺酮类化学合成抑菌剂,主要用于治疗动物的感染性疾病。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062300002376.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2444755260","title":"京新药业:公司与万邦医药没有关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2444755260","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444755260?lang=zh_cn&edition=full","pubTime":"2024-06-20 17:03","pubTimestamp":1718874187,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业06月20日在投资者关系平台上答复投资者关心的问题。公司与万邦医药没有关系。公司实际控制人及持股5%以上的股东没有参与转融通业务,公司会严格遵守信披规定,对大股东的须披露交易和市场行为进行披露。另外,公司前十大股东信息请关注公司定期报告披露内容,根据公司2024年第一季度报告,泰康人寿不是当期前十大股东之一。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000033325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","002020","301520","BK0239"],"gpt_icon":0},{"id":"2444223580","title":"京新药业(002020)6月19日主力资金净卖出2194.77万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2444223580","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444223580?lang=zh_cn&edition=full","pubTime":"2024-06-20 09:20","pubTimestamp":1718846420,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年6月19日收盘,京新药业报收于10.71元,下跌3.16%,换手率1.9%,成交量12.47万手,成交额1.35亿元。近5日资金流向一览见下表:京新药业融资融券信息显示,融资方面,当日融资买入1489.23万元,融资偿还680.72万元,融资净买入808.51万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000013122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2441032409","title":"京新药业:该项目的国外合作方还在申报FDA阶段,目前正在跟进进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2441032409","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441032409?lang=zh_cn&edition=full","pubTime":"2024-06-07 17:04","pubTimestamp":1717751087,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)06月07日在投资者关系平台上答复投资者关心的问题。投资者:请问洪总,公司的静脉桥外支架最新进展情况是怎样了?京新药业董秘:您好!该项目的国外合作方还在申报FDA阶段,目前正在跟进进展。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060700033571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2440468053","title":"京新药业:公司经营一切正常,不存在ST风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2440468053","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440468053?lang=zh_cn&edition=full","pubTime":"2024-06-03 18:05","pubTimestamp":1717409124,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业06月03日在投资者关系平台上答复投资者关心的问题。近期有些公司突然被ST,就目前来说公司存在被ST的风险吗?公司经营一切正常,不存在ST风险。内蒙公司的经营情况?年产30亿粒固体制剂产能提升项目已完工,目前在产品验证转移中,进展正常。内蒙京新生产经营正常,新厂区已经投产,并在逐渐承接沙溪制药的部分品种的生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300023135.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2439903596","title":"京新药业:公司人工大血管项目目前已经进入到小规模人体试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2439903596","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439903596?lang=zh_cn&edition=full","pubTime":"2024-05-30 17:03","pubTimestamp":1717059801,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业05月30日在投资者关系平台上答复投资者关心的问题。公司人工大血管项目目前已经进入到小规模人体试验阶段。公司会严格遵守信披规定,对大股东的须披露交易和市场行为进行披露。医院采购新的品种,必须通过医院药事会批准等程序。有关业绩情况敬请关注公司定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024053000031188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2437083546","title":"京新药业:由于京诺宁是精二类管制品种,只能在院内处方和配药,因此入院工作在前期至关重要","url":"https://stock-news.laohu8.com/highlight/detail?id=2437083546","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437083546?lang=zh_cn&edition=full","pubTime":"2024-05-24 17:04","pubTimestamp":1716541466,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业05月24日在投资者关系平台上答复投资者关心的问题。京诺宁的销售工作正在有序顺利进行。公司就入院工作进行了缜密部署,把它作为今年的重点工作来推进。由于京诺宁是精二类管制品种,只能在院内处方和配药,因此入院工作在前期至关重要。有了广泛入院作为基础,未来的销售才能发力。京诺宁和之前的同类药物相比,有明显的机制创新优势,在疗效上也有充分体现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052400033120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2437413715","title":"京新药业:主要是费用的年度预提","url":"https://stock-news.laohu8.com/highlight/detail?id=2437413715","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437413715?lang=zh_cn&edition=full","pubTime":"2024-05-21 19:02","pubTimestamp":1716289372,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业(002020)05月21日在投资者关系平台上答复投资者关心的问题。投资者:请教公司财务总监,公司其他应付款规模有5个多亿,这个款项性质是什么呢,年报中就披露了账龄京新药业董秘:您好!主要是费用的年度预提。谢谢!以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052100031536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2435755106","title":"京新药业(002020.SZ)2023年度权益分派:每10股派3元 股权登记日5月23日","url":"https://stock-news.laohu8.com/highlight/detail?id=2435755106","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435755106?lang=zh_cn&edition=full","pubTime":"2024-05-16 19:05","pubTimestamp":1715857556,"startTime":"0","endTime":"0","summary":"智通财经APP讯,京新药业(002020.SZ)发布公告,公司2023年年度权益分派方案为:以公司现有总股本为基数,向全体股东每10股派3.00元人民币现金(含税),本次权益分派股权登记日为:2024年5月23日,除权除息日为:2024年5月24日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1122155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2434109334","title":"京新药业:年度股东大会已经通过年度分红议案,公司将在规定时间内完成","url":"https://stock-news.laohu8.com/highlight/detail?id=2434109334","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434109334?lang=zh_cn&edition=full","pubTime":"2024-05-09 19:02","pubTimestamp":1715252528,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业05月09日在投资者关系平台上答复投资者关心的问题。作为一款十几年来失眠领域首次上市的新药,京诺宁初期的目标还是通过学术推广,让更多的医院和医生认可它的疗效和安全性,从而为将来大规模推广奠定基础。京诺宁正式商业发货一个多月以来,已经有多家医院完成入院手续,一些医院也已经进入到入院流程。公司今年的主要目标是尽可能多地覆盖头部医院和专科医院。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900034266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2433738619","title":"京新药业:公司暂无扩大睿泰投资的计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2433738619","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433738619?lang=zh_cn&edition=full","pubTime":"2024-05-08 00:00","pubTimestamp":1715097638,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业05月07日在投资者关系平台上答复投资者关心的问题。投资者:公司投资的上海睿泰,现在占比12.4%是第五大股东,未来会不会对上海睿泰扩大投资比例让其成为子公司,拓展再生生物业务,完善医药+医疗的布局。公司暂无扩大睿泰投资的计划。目前沙溪制药的一部分品种的生产,正有序地向内蒙新产区转移。公司安宫牛黄丸已于2022年下半年上市,目前暂未在京东和天猫平台旗舰店内销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800000002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2432131106","title":"京新药业公布国际专利申请:“配体-寡核苷酸共轭物及用于该共轭物的接头”","url":"https://stock-news.laohu8.com/highlight/detail?id=2432131106","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432131106?lang=zh_cn&edition=full","pubTime":"2024-05-04 04:31","pubTimestamp":1714768262,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示京新药业公布了一项国际专利申请,专利名为“配体-寡核苷酸共轭物及用于该共轭物的接头”,专利申请号为PCT/CN2023/125626,国际公布日为2024年4月25日。专利详情如下:图片来源:世界知识产权组织今年以来京新药业已公布的国际专利申请1个。结合公司2023年年报财务数据,2023年公司在研发方面投入了4.01亿元,同比增9.23%。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050400003337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2431832830","title":"京新药业:针对京诺宁,公司目前仍然以国内市场为重点,时机合适也将推动海外市场拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2431832830","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431832830?lang=zh_cn&edition=full","pubTime":"2024-04-29 19:02","pubTimestamp":1714388574,"startTime":"0","endTime":"0","summary":"证券之星消息,京新药业04月29日在投资者关系平台上答复投资者关心的问题。公司会围绕京诺宁新机制带来的疗效提升,尽快推动市场拓展和其他各项工作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900025215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002020"],"gpt_icon":0},{"id":"2430871877","title":"京新药业获得发明专利授权:“一种左乙拉西坦的制备方法”","url":"https://stock-news.laohu8.com/highlight/detail?id=2430871877","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430871877?lang=zh_cn&edition=full","pubTime":"2024-04-27 02:47","pubTimestamp":1714157248,"startTime":"0","endTime":"0","summary":"证券之星消息,根据企查查数据显示京新药业新获得一项发明专利授权,专利名为“一种左乙拉西坦的制备方法”,专利申请号为CN202211010560.6,授权日为2024年4月26日。今年以来京新药业新获得专利授权2个,较去年同期减少了33.33%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042700005868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020","BK0239"],"gpt_icon":0},{"id":"2430669440","title":"太平洋:给予京新药业买入评级,目标价位18.42元","url":"https://stock-news.laohu8.com/highlight/detail?id=2430669440","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430669440?lang=zh_cn&edition=full","pubTime":"2024-04-25 13:50","pubTimestamp":1714024237,"startTime":"0","endTime":"0","summary":"太平洋证券股份有限公司周豫,刘哲涵近期对京新药业进行研究并发布了研究报告《Q1业绩超预期,盈利能力改善》,本报告对京新药业给出买入评级,认为其目标价位为18.42元,当前股价为11.44元,预期上涨幅度为61.01%。考虑公司院内集采影响出清,院外市场提升空间大,创新药持续提供增量,维持“买入”评级,维持目标价18.42元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500024739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","002020"],"gpt_icon":0},{"id":"2430492313","title":"京新药业(002020)2024年一季报简析:营收净利润同比双双增长,盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2430492313","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430492313?lang=zh_cn&edition=full","pubTime":"2024-04-25 06:11","pubTimestamp":1713996661,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期京新药业发布2024年一季报。根据财报显示,本报告期中京新药业营收净利润同比双双增长,盈利能力上升。截至本报告期末,公司营业总收入10.61亿元,同比上升10.44%,归母净利润1.71亿元,同比上升13.23%。营收分析方面,公司最新一期年度报表的现金流为正,经营性现金流和利润相匹配。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042500011843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002020"],"gpt_icon":0},{"id":"2429481028","title":"平安证券:给予京新药业增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2429481028","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429481028?lang=zh_cn&edition=full","pubTime":"2024-04-24 16:37","pubTimestamp":1713947841,"startTime":"0","endTime":"0","summary":"平安证券股份有限公司叶寅,韩盟盟,臧文清近期对京新药业进行研究并发布了研究报告《24Q1业绩重回长期增长轨道,盈利能力持续优化》,本报告对京新药业给出增持评级,当前股价为11.24元。 平安观点: 公司24Q1收入端恢复较快增长,利润端重回长期增长轨道。公司首个1类新药,适用于失眠患者短期治疗的地达西尼胶囊于24年3月底正式上市销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400033329.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","002020"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2004-07-15","address":"浙江省绍兴市新昌县羽林街道新昌大道东路800号","stockEarnings":[{"period":"1week","weight":-0.0384},{"period":"1month","weight":-0.0058},{"period":"3month","weight":-0.0726},{"period":"6month","weight":0.0062},{"period":"1year","weight":-0.1552},{"period":"ytd","weight":-0.1718}],"companyName":"浙江京新药业股份有限公司","boardCode":"AI0027","perCapita":"33079股","boardName":"医药制造业","registeredCapital":"86102万元","compareEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":-0.0206},{"period":"3month","weight":-0.0494},{"period":"6month","weight":-0.0028},{"period":"1year","weight":-0.102},{"period":"ytd","weight":-0.0245}],"survey":" 浙江京新药业股份有限公司主要从事化学制剂、传统中药、生物制剂、化学原料药、医疗器械的研发、生产及销售。公司的主要产品为心脑血管药物、神经系统药物、消化系统药物、呼吸系统药物、泌尿生殖系统药物、喹诺酮类抗感染原料药、他汀类原料药、精神类原料药、定制化医用显示器和HMI、标准化医用显示器及医疗影像解决方案。公司是第一批“中国医药企业制剂国际化先导企业”,连续多年荣登“中国化学制药行业制剂出口型优秀企业品牌”、“中国医药工业百强”和“中国化学制药企业百强榜”。","serverTime":1721844903067,"listedPrice":10.05,"stockholders":"167174人(较上一季度增加443.71%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"京新药业,002020,京新药业股票,京新药业股票老虎,京新药业股票老虎国际,京新药业行情,京新药业股票行情,京新药业股价,京新药业股市,京新药业股票价格,京新药业股票交易,京新药业股票购买,京新药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"京新药业(002020)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供京新药业(002020)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}